首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1475211

全球促红血球生成素药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Erythropoietin Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球促红血球生成素药物市场需求预计将从2023年的89.7亿美元达到2032年近131.1亿美元的市场规模，2024-2032年研究期间的复合年增长率为4.31%。

促红血球生成素药物是一种模仿内源性促红血球生成素作用的药剂，内源性红血球生成素是一种由肾臟产生的激素，控制骨髓中红血球的生成。这些药物用于治疗与慢性肾臟病、癌症化疗、爱滋病毒/爱滋病以及其他导致红血球生成减少或红血球损失增加的疾病相关的贫血。这些药物有助于增加血红素水平，提高氧气输送能力，缓解疲劳和虚弱等贫血症状，并减少红血球生成功能受损患者的输血需求。

市场动态

慢性肾臟病 (CKD)、癌症相关贫血和其他血液疾病的发生率不断上升，推动了对促红血球生成素药物的需求，将其作为刺激红血球生成、控制贫血症状和改善患者生活品质的基本治疗方法。由于人口老化、生活方式相关疾病以及慢性病患病率上升等因素造成全球贫血负担，人们越来越需要有效的促红血球生成素疗法，为患者提供有针对性的个人化治疗选择。此外，生物製药製造、蛋白质工程和药物传输技术的进步使得能够开发出具有改进的药物动力学、稳定性和功效特征的下一代促红血球生成素药物，从而增强其治疗潜力和临床实用性。此外，促红血球生成素疗法的应用范围不断扩大，超越了运动医学、伤口癒合和神经保护等传统适应症，推动了对新型促红血球生成素製剂和输送系统的需求，这些製剂和输送系统可以解决未满足的医疗需求，并为不同的患者群体提供创新的解决方案。

此外，全球临床实践和医疗保健系统中越来越多地采用生物仿製药、生物改良剂和新型红血球生成刺激剂(ESA)，推动了市场竞争、定价动态和促红血球生成素药物的获取，为药品製造商、医疗保健提供者、和病人。随着人们越来越关注基于价值的医疗保健、以患者为中心的方法和循证医学，需要製定全面的策略来优化促红血球生成素治疗结果、确保患者安全并提高医疗保健系统效率。然而，专利到期、仿製药竞争和定价压力可能会挑战未来几年的市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球促红血球生成素药物市场的各个细分市场进行了包容性评估。促红血球生成素药物产业的成长和趋势为本研究提供了整体方法。

市场区隔

促红血球生成素药物市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略家确定相应产品或服务的目标人群以及即将到来的机会。

按药物类别

阿尔法依泊汀
β依泊汀
达贝泊汀阿尔法
其他的

依药物类型

生物製剂
生物相似药

按药物应用

癌症
肾臟疾病
血液学
神经病学
其他的

按配销通路

医院药房
零售药房
网路药房

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲促红血球生成素药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。促红血球生成素药物市场的主要参与者包括安进公司、诺华公司、罗氏公司、葛兰素史克、默克公司、强生公司、沃克哈特有限公司、辉瑞公司、百康有限公司.，梯瓦製药工业有限公司。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

简介 - 市场动态
市场驱动因素
市场限制
机会
产业动态
波特五力分析
市场吸引力分析
- 按药品类别分類的市场吸引力分析
- 按药物类型分類的市场吸引力分析
- 按药物应用分類的市场吸引力分析
- 按配销通路分類的市场吸引力分析
- 市场吸引力分析：按地区

第 4 章：价值链分析

价值链分析
原料分析
- 原料清单
- 原料厂商清单
- 主要原物料价格走势
潜在买家名单
行销管道
- 直效行销
- 间接行销
- 行销通路发展趋势

第 5 章：全球促红血球生成素药物市场分析：依药物类别

按药物类别概述
历史和预测数据
按药物类别分析
阿尔法依泊汀
β依泊汀
达贝泊汀阿尔法
其他的

第 6 章：全球促红血球生成素药物市场分析：依药物类型

按药物类型概述
历史和预测数据
依药物类型分析
生物製剂
生物相似药

第 7 章：全球促红血球生成素药物市场分析：依药物应用分类

按药物应用概述
历史和预测数据
按药物应用分析
癌症
肾臟疾病
血液学
神经病学
其他的

第 8 章：全球促红血球生成素药物市场分析：按分销管道

配销通路概览
历史和预测数据
按配销通路分析
医院药房
零售药房
网路药房

第 9 章：全球促红血球生成素药物市场分析：依地理位置

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 10 章：促红血球生成素药物公司的竞争格局

促红血球生成素药物市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 11 章：公司简介

顶级公司市占率分析
市场集中度
Amgen Inc.

公司简介
公司收入
产品
最近的发展

Novartis AG

公司简介
公司收入
产品
最近的发展

F. Hoffmann-La Roche Ltd.

公司简介
公司收入
产品
最近的发展

公司简介
公司收入
产品
最近的发展

Merck & Co. Inc.

公司简介
公司收入
产品
最近的发展

Johnson & Johnson

公司简介
公司收入
产品
最近的发展

Wockhardt Ltd.

公司简介
公司收入
产品
最近的发展

Pfizer Inc.

公司简介
公司收入
产品
最近的发展

Biocon Ltd.

公司简介
公司收入
产品
最近的发展

Teva Pharmaceutical Industries Ltd.

公司简介
公司收入
产品
最近的发展

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112114340

The global demand for Erythropoietin Drugs Market is presumed to reach the market size of nearly USD 13.11 Billion by 2032 from USD 8.97 Billion in 2023 with a CAGR of 4.31% under the study period 2024 - 2032.

Erythropoietin drugs are pharmaceutical agents that mimic the action of endogenous erythropoietin, a hormone produced by the kidneys that controls the generation of red blood cells in the bone marrow. These drugs are used to treat anemia associated with chronic kidney disease, cancer chemotherapy, HIV/AIDS, and other medical conditions that result in reduced red blood cell generation or heightened loss of red blood cells. These drugs help increase hemoglobin levels, improve oxygen transport capacity, alleviate symptoms of anemia such as fatigue and weakness, and reduce the need for blood transfusions in patients with compromised erythropoietic function.

MARKET DYNAMICS

The escalating incidence of chronic kidney disease (CKD), cancer-related anemia, and other hematological disorders drives the demand for erythropoietin drugs as essential treatments to stimulate red blood cell production, manage anemia symptoms, and improve patients' quality of life. With factors such as aging populations, lifestyle-related diseases, and the rising prevalence of chronic conditions contributing to the global burden of anemia, there is a growing need for effective erythropoietin therapies that offer targeted and personalized treatment options for patients. Additionally, advancements in biopharmaceutical manufacturing, protein engineering, and drug delivery technologies enable the development of next-generation erythropoietin drugs with improved pharmacokinetics, stability, and efficacy profiles, enhancing their therapeutic potential and clinical utility. Moreover, the expanding applications of erythropoietin therapy beyond traditional indications, such as sports medicine, wound healing, and neuroprotection, drive the demand for novel erythropoietin formulations and delivery systems that address unmet medical needs and offer innovative solutions for diverse patient populations.

Furthermore, the increasing adoption of biosimilars, biobetters, and novel erythropoiesis-stimulating agents (ESAs) in clinical practice and healthcare systems worldwide drives market competition, pricing dynamics, and access to erythropoietin drugs, creating opportunities and challenges for drug manufacturers, healthcare providers, and patients. With the growing focus on value-based healthcare, patient-centered approaches, and evidence-based medicine, there is a need for comprehensive strategies that optimize erythropoietin therapy outcomes, ensure patient safety, and enhance healthcare system efficiency. However, patent expirations, generic competition, and pricing pressures may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of erythropoietin drugs. The growth and trends of erythropoietin drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the erythropoietin drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Epoetin Alfa
Epoetin Beta
Darbepoetin Alfa
Others

By Drug Type

Biologics
Biosimilar

By Drug Application

Cancer
Renal Disease
Hematology
Neurology
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Erythropoietin Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Erythropoietin Drugs market include Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd., GSK, Merck & Co., Inc., Johnson & Johnson, Wockhardt Ltd., Pfizer, Inc., Biocon Ltd., Teva Pharmaceutical Industries Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ERYTHROPOIETIN DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Drug Type
- 3.7.3 Market Attractiveness Analysis By Drug Application
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ERYTHROPOIETIN DRUGS MARKET ANALYSIS BY DRUG CLASS

5.1. Overview By Drug Class
5.2. Historical and Forecast Data
5.3. Analysis By Drug Class
5.4. Epoetin Alfa Historic and Forecast Sales By Regions
5.5. Epoetin Beta Historic and Forecast Sales By Regions
5.6. Darbepoetin Alfa Historic and Forecast Sales By Regions
5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL ERYTHROPOIETIN DRUGS MARKET ANALYSIS BY DRUG TYPE

6.1. Overview By Drug Type
6.2. Historical and Forecast Data
6.3. Analysis By Drug Type
6.4. Biologics Historic and Forecast Sales By Regions
6.5. Biosimilar Historic and Forecast Sales By Regions

7. GLOBAL ERYTHROPOIETIN DRUGS MARKET ANALYSIS BY DRUG APPLICATION

7.1. Overview By Drug Application
7.2. Historical and Forecast Data
7.3. Analysis By Drug Application
7.4. Cancer Historic and Forecast Sales By Regions
7.5. Renal Disease Historic and Forecast Sales By Regions
7.6. Hematology Historic and Forecast Sales By Regions
7.7. Neurology Historic and Forecast Sales By Regions
7.8. Others Historic and Forecast Sales By Regions

8. GLOBAL ERYTHROPOIETIN DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data
8.3. Analysis By Distribution Channel
8.4. Hospital Pharmacy Historic and Forecast Sales By Regions
8.5. Retail Pharmacy Historic and Forecast Sales By Regions
8.6. Online Pharmacy Historic and Forecast Sales By Regions

9. GLOBAL ERYTHROPOIETIN DRUGS MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ERYTHROPOIETIN DRUGS COMPANIES

10.1. Erythropoietin Drugs Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF ERYTHROPOIETIN DRUGS INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Amgen Inc.
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. Novartis AG
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. F. Hoffmann-La Roche Ltd.
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. GSK
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. Merck & Co. Inc.
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. Johnson & Johnson
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. Wockhardt Ltd.
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Pfizer Inc.
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. Biocon Ltd.
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. Teva Pharmaceutical Industries Ltd.
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments